AOHome OCT-Guided Treatment vs. Treat and Extend for Neovascular AMD Management

This study focuses on treating Neovascular Age-Related Macular Degeneration (nAMD), a condition that affects the eyes. Currently, treatment involves anti-vascular endothelial growth factor therapy, which is effective but comes with a high treatment burden and cost. The study aims to find a more personalized approach to manage nAMD, potentially reducing the treatment burden. It uses a home Optical Coherence Tomography (OCT) device for daily disease monitoring, which could lead to better visual acuity outcomes and fewer injections. The study is important as it could improve the quality of life for nAMD patients and reduce healthcare costs. Participants in this study will first undergo eligibility assessment, vision testing, ocular examination, and various imaging. They will also receive an initial injection of faricimab. If eligible, participants will be randomly assigned to one of two groups: the Treat and Extend group or the Home OCT-guided treatment group. The Treat and Extend group will have regular visits every 4-18 weeks, while the Home OCT group will self-scan daily using the Home OCT device and only return for a visit if certain conditions are met. The study's primary outcomes are the comparison of visual acuity and the number of injections between the two groups over a period of 104 weeks.